摘要
目的探讨渴乐宁胶囊联合格列齐特缓释片治疗2型糖尿病临床疗效。方法选取2017年3月—2018年3月在漯河市中心医院治疗的2型糖尿病患者92例,根据入院号分为对照组(46例)和治疗组(46例)。对照组口服格列齐特缓释片,初始剂量30 mg/次,1次/d,根据患者血糖情况每间隔14 d增加1片,血糖控制后30 mg/次,1次/d;治疗组在对照组基础上口服渴乐宁胶囊,1.80g/次,3次/d。两组均治疗4周。观察两组患者临床疗效,同时比较治疗前后两组患者空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1c)、胰岛素(FINS)、超敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)、单核细胞趋化蛋白-1(MCP-1)、肿瘤坏死因子-α(TNF-α)、脂联素(APN)、瘦素(LP)和皮质醇(Cor)水平。结果治疗后,对照组和治疗组临床有效率分别为82.61%和97.82%,两组比较差异具有统计学意义(P<0.05)。治疗后两组FPG、2 h PG、HbAlc、FINS、hs-CRP、MCP-1、IL-1β和TNF-α水平均显著下降(P<0.05),且治疗后治疗组上述血糖和炎性指标水平明显低于对照组(P<0.05)。治疗后,两组LP、Cor水平均显著下降(P<0.05),APN水平显著上升(P<0.05),且治疗组LP、Cor和APN水平明显好于对照组(P<0.05)。结论渴乐宁胶囊联合格列齐特缓释片治疗2型糖尿病可有效控制患者血糖水平,降低机体炎症反应,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of Kelening Capsules combined with gliclazide in treatment of type 2 diabetes mellitus. Methods Patients(92 cases) with type 2 diabetes mellitus in Luohe Central Hospital from March 2017 to March 2018 were randomly divided into control(46 cases) and treatment(46 cases) groups. Patients in the control group were po administered with Gliclazide Modified Release Tablets, the initial dose was 30 mg/kg, once daily, and then increased 1 tablet every 14 d based on blood glucose, 30 mg/kg after controlling blood glucose, once daily. Patients in the treatment group were po administered with Kelening Capsules on the basis of the control group, 1.80 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the FPG, 2 h PG, HbAlc, FINS, hs-CRP, MCP-1, IL-1β and TNF-α, LP, Cor and APN levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 82.61% and 97.82% respectively, and there were differences between two groups(P < 0.05). After treatment, the FPG, 2 h PG, HbAlc, FINS, hs-CRP, MCP-1, IL-1β and TNF-α levels in two groups were significantly decreased(P < 0.05), and these blood glucose related indicators and inflammatory indexes levels in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the LP and Cor levels in two groups were significantly decreased(P < 0.05), but APN levels were significantly increased(P < 0.05). After treatment, the LP, Cor and APN levels in the treatment group were significantly better than those in the control group(P < 0.05). Conclusion Kelening Capsules combined with gliclazide in treatment of type 2 diabetes mellitus can effectively control blood glucose levels and reduce inflammation, which has a certain clinical application value.
作者
杨晓玉
陈思
杨艳冰
杨静
YANG Xiao-yu;CHEN Si;YANG Yan-bing;YANG Jing(Department of Pharmacy,Luohe Central Hospital,Luohe 462000,China;Operating Theatre,Shaoling District People's Hospital of Luohe City,Luohe 462000,China;Department of Respiration,Luohe Central Hospital,Luohe 462000,China;Department of Medical Examination,Fangcheng County People's Hospital,Nanyang 473200,China)
出处
《现代药物与临床》
CAS
2019年第2期489-493,共5页
Drugs & Clinic
